Skip to main content
Equibles
RARE logo

RARE · Ultragenyx Pharmaceutical Inc. · Metrics

Track RARE — free

Use RARE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RARE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.08 +0.43 (+2.75%) At close · Oct 26
Russell 2000 member Rebalance outlook locked
Market Cap
$1.54B
Shares
98.59M
Volume · Oct 26 3.02M Avg daily vol (3M) 4.12M

RARE metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$16.08
Market cap
$1.54B

Price action

20 metrics
Price change (1W)
+7.6%
Price change (30D)
+8.6%
Price change (3M)
-41.8%
Price change (6M)
-35.1%
Price change (YTD)
-32.0%
Price change (1Y)
-53.5%
Trailing year
Price change (5Y)
-80.0%
52-week high
$36.54
52-week low
$12.88
Change from 52-week high
-57.2%
Change from 52-week low
+21.5%
Annualized volatility
81.7%
Annualized volatility (3M)
100.7%
Beta
1.3
RSI (14D)
47.7
Price vs SMA 50
-12.8%
Price vs SMA 200
-32.2%
Avg volume (3M)
4.09M
Relative volume
0.4
Average dollar volume
$71.75M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
98.59M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.2×
reciprocal yield 46.5%
P / book
—
FCF yield
-31.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-38.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
—
Operating margin
-73.6%
Trailing 12 months
Net margin
-81.7%
Gross profit (TTM)
$68.35M
Operating profit (TTM)
−$528.00M
Net income (TTM)
−$586.00M
Trailing 12 months
Diluted EPS (TTM)
$-5.83
FCF margin
-68.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$7.13
Gross profit per diluted share (TTM)
$1.28
Operating profit per diluted share (TTM)
$-5.26
EBITDA per diluted share (TTM)
$-4.93
Net income per diluted share (TTM)
$-5.84
Operating cash flow per diluted share (TTM)
$-4.82
Free cash flow per diluted share (TTM)
$-4.86
Capital expenditures per diluted share (TTM)
$0.04
R&D per diluted share (TTM)
$7.70
Stock compensation per diluted share (TTM)
$1.63
Book value per share
$-0.83

Growth

11 metrics
Revenue growth YoY
+28.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$717.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.5%
Year over year · more shares
Revenue CAGR (3Y)
+22.8%
Revenue CAGR (5Y)
+19.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-46.4%
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
−$495.00M
Free cash flow (TTM)
−$489.00M
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$125.00M
Latest balance sheet
Cash & equivalents
$125.00M
Total assets
$1.26B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$485.00M
Capital expenditures (TTM)
$4.00M
R&D (TTM)
$773.00M
SG&A (TTM)
$351.00M
Stock compensation (TTM)
$75.08M
R&D / revenue
107.8%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
317
13F filer change QoQ
+19
Institutional ownership
112.0%
Conviction holders (share of 13F filers)
2.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.2%
Holder tenure
12.8
Price vs estimated holder cost
+15.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.4%

Short interest

3 metrics
Short interest
20.4%
Latest settlement · 5.2 days to cover
Days to cover
5.2d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$291,933
Insider-sentiment score
42 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1515673 CUSIP 90400D108 13F (30d) 26 filings 26 filers Visit website Investor relations